A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- David Hsieh
- Target Recruit Count
- 35
- Registration Number
- NCT03519997
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath